Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

Investors seeking to compare Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) for potential investment in 2027 should weigh the strengths and weaknesses of each company, taking into account their financial health, risk profiles, and growth prospects.

Bristol Myers Squibb, a diversified drug manufacturer, boasts a vast global infrastructure and several blockbuster treatments, particularly in oncology, hematology, and neuroscience. The company reported a slight decline in revenue for FY 2025, reaching around $48.2 billion, but demonstrated a strong net income of approximately $7.1 billion, resulting in a net margin of 14.6%.

Its debt-to-equity ratio stands at 2.6x, indicating a moderate level of leverage, while its current ratio of 1.3x signifies sufficient liquidity to meet short-term obligations. With free cash flow of about $12.8 billion, BMY maintains a robust financial position.

Vertex Pharmaceuticals, a focused biotechnology leader, specializes in creating near-monopolies in specific disease niches, such as cystic fibrosis and sickle cell disease. The company reported a revenue increase of approximately 9.6% in FY 2025, reaching around $12.1 billion, with a net income of around $4.0 billion and a net margin of 32.7%.

Vertex's debt-to-equity ratio is much lower at 0.2x, reflecting its conservative financial structure. Its current ratio of 2.9x indicates strong liquidity. With free cash flow of about $3.2 billion, Vertex has the financial flexibility to fund ongoing research and development efforts.

When comparing the two companies, BMY appears more appealing from a valuation perspective, with lower valuation multiples. However, VRTX's higher growth potential and profit margins make it an attractive option for investors seeking substantial upside. The cystic fibrosis franchise at Vertex continues to show promise, with upcoming approvals of its next-generation therapies, such as Alyftrek and Povetacicept, which could significantly boost annual sales and generate revenues potentially reaching $4 billion to $7 billion by fiscal 2026.

In conclusion, investors should carefully consider the relative strengths and weaknesses of both BMY and VRTX, keeping in mind their respective financials, risk profiles, and growth potential. BMY offers a more conservative investment with lower risks, while VRTX presents an opportunity for higher growth and substantial profits, particularly in the field of cystic fibrosis. Ultimately, the choice between these two pharmaceutical stocks will depend on an investor's risk tolerance and investment strategy for 2027.